Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Development of First-in-Class Lysine-Targeting Kinase Inhibitors for the Treatment of Lung Carcinomas
EF 2023-24
Résumé
Lung cancer is attributed to almost one-fifth of the total deaths worldwide and ~85% of these cases are non-small cell lung cancer (NSCLC). Although there are several proposed causes of NSCLC, one of the key oncogenic drivers has been linked to specific kinases of the RAS/RAF/MEK/ERK signaling pathway. Importantly, this pathway is also upregulated in 50% of all cancers, highlighting the biochemical and clinical importance of blockading this pathway. Unfortunately, several pharmacological efforts failed due to a lack of well-defined binding pockets for several proteins along with pathway, and the presence of key driver mutations further complicates drug discovery efforts. In our approach, we have developed and synthesized novel lysine-targeting warheads that we have appended onto kinase hinge-binding scaffolds via computationally-aided drug design. By carefully manipulating the positioning of the lysine-directed warheads we have been able to develop potency for a range of kinases, including high-value kinase targets in lung cancer. We have profiled a selection of these molecules against 300 kinases which have demonstrated these molecules can show high selectivity with specific kinases of the RAS/RAF/MEK/ERK pathway. Our objectives are focused on optimizing pharmacokinetic parameters of the molecules in order to evaluate their efficacy in advanced preclinical models.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
506534
Name
Patel Naman
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of First-in-Class Lysine-Targeting Kinase Inhibitors for the Treatment of Lung Carcinomas
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Covalent; Inhibition; Kinase; Lysine; Novel; Potent; Selective; Stability; Therapeutic
Abstract
Lung cancer is attributed to almost one-fifth of the total deaths worldwide and ~85% of these cases are non-small cell lung cancer (NSCLC). Although there are several proposed causes of NSCLC, one of the key oncogenic drivers has been linked to specific kinases of the RAS/RAF/MEK/ERK signaling pathway. Importantly, this pathway is also upregulated in 50% of all cancers, highlighting the biochemical and clinical importance of blockading this pathway. Unfortunately, several pharmacological efforts failed due to a lack of well-defined binding pockets for several proteins along with pathway, and the presence of key driver mutations further complicates drug discovery efforts. In our approach, we have developed and synthesized novel lysine-targeting warheads that we have appended onto kinase hinge-binding scaffolds via computationally-aided drug design. By carefully manipulating the positioning of the lysine-directed warheads we have been able to develop potency for a range of kinases, including high-value kinase targets in lung cancer. We have profiled a selection of these molecules against 300 kinases which have demonstrated these molecules can show high selectivity with specific kinases of the RAS/RAF/MEK/ERK pathway. Our objectives are focused on optimizing pharmacokinetic parameters of the molecules in order to evaluate their efficacy in advanced preclinical models.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Patel, Naman
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~